| Literature DB >> 34626296 |
Tanyeri Barak1,2,3, Shaurey Vetsa1,2, Arushii Nadar1,2, Lan Jin1,2,4,5, Trisha P Gupte1,2, Elena I Fomchenko1,2, Danielle F Miyagishima1,2, Kanat Yalcin1, Sagar Vasandani1,2, Evan Gorelick1,2, Amy Y Zhao1,2, Joseph Antonios1,2, Brianna Carusillo Theriault1,2, Nathan Lifton1,2, Neelan Marianayagam1,2, Bulent Omay1,2, Zeynep Erson Omay1,2, Anita Huttner2,6, Declan McGuone2,6, Nicholas A Blondin2,7, Zachary Corbin2,7, Robert K Fulbright2,8, Jennifer Moliterno9,10.
Abstract
OBJECTIVE: While adjuvant treatment regimens have been modified for older patients with glioblastoma (GBM), surgical strategies have not been tailored.Entities:
Keywords: Glioblastoma; Intraoperative imaging; Neuronavigation; Surgical strategies
Mesh:
Year: 2021 PMID: 34626296 PMCID: PMC8651607 DOI: 10.1007/s11060-021-03862-z
Source DB: PubMed Journal: J Neurooncol ISSN: 0167-594X Impact factor: 4.506
General patient characteristics and comparative analysis between ioUS and combined ioMRI + ioUS groups
| Characteristics | Total | IoUS | ioUS+IoMRI | P value |
|---|---|---|---|---|
| Age in Years (Mean ± SD) | 75.98 ± 4.99 | 80.16 ± 5.99 | 74.43 ± 3.36 |
|
| Gender | ||||
| Female | 20 | 3 (23.08%) | 17 | 0.188 |
| Male | 28 | 10 (76.92%) | 18 | |
| Presentation | ||||
| Altered mental status | 17 (35.42%) | 5 (38.46%) | 12 (34.29 %) | 1 |
| Facial strength | 9 (18.75%) | 2 (15.38%) | 7 (20 %) | 1 |
| Language/Speech deficit | ||||
| Seizures | 5 (10.42%) | 2 (15.38%) | 3 (8.57%) | 0.602 |
| Motor deficit and Ataxia | 16 (33.33%) | 6 (46.15%) | 10 (28.57%) | 0.311 |
| Visual field cut | 10 (20.83%) | 1 (7.69%) | 9 (25.71%) | 0.248 |
| Past medical history | 44 (91.67%) | 12 (92.31%) | 32 (91.43%) | 1 |
| Hypertension | 27 (56.25%) | 7 (53.85%) | 20 (57.14%) | 1 |
| Diabetes Mellitus | 9 (18.75%) | 1 (7.69%) | 8 (22.86%) | 0.411 |
| Hyperlipidemia | 23 (47.92%) | 6 (46.1 %) | 17 (48.57%) | 1 |
| Thyroid disorder | 5 (10.42%) | 0 | 5 (14.29%) | 0.304 |
| DVT/PE | 4 (8.33%) | 1 (7.69 %) | 3 (8.57%) | 1 |
|
| 17 (35.42 %) | 8 (61.54 %) | 9 (25.71%) | 0.039 |
| Arrhythmia | 9 (18.75 %) | 4 (30.77 %) | 5 (14.29%) | 0.228 |
| Stroke | 4 (8.33 %) | 2 (15.38 %) | 2 (5.71%) | 0.294 |
| CAD | 4 (8.33%) | 2 (15.38%) | 2 (5.71%) | 0.294 |
| Aortic aneurysm | 3 (6.25%) | 3 (23.08%) | 0 | |
| Aortic stenosis | 2 (4.16%) | 1 (7.69%) | 1 (2.86%) | 0.473 |
| Localization | ||||
| Right | 32 (66.67%) | 7 (53.85%) | 25 (71.43%) | 0.311 |
| Left | 16 (33.33%) | 6 (46.15%) | 10 (28.57%) | |
| Anatomic classification | ||||
| Supratentorial | 47 (97.92%) | 13 (100%) | 34 (97.14%) | 1 |
| Infratentorial | 1 (2.08%) | 0 | 1 (2.86%) | |
| Location | ||||
| Frontal | 15 (31.25 %) | 4 (30.77%) | 11 (31.43%) | 1 |
| Temporal | 22 (45.83 %) | 6 (46.15%) | 16 (45.71%) | 1 |
| Parietal | 16 (33.33 %) | 5 (38.46%) | 11 (31.43%) | 0.735 |
| Occipital | 3 (6.25%) | 1 (7.69%) | 2 (5.71%) | 1 |
| Multilobar | 8 (16.67%) | 3 (23.08%) | 5 (14.29%) | 0.665 |
| Multifocal | 1 (2.08 %) | 1 (7.69%) | 0 | 0.271 |
| Eloquent structure involvement | 16 (33.33 %) | 5 (38.46%) | 11 (31.43%) | 0.735 |
| Basal Ganglia | 6 (12.50%) | 3 (23.08%) | 3 (8.57%) | 0.323 |
| Insula | 8 (16.67%) | 1 (7.69%) | 7 (20%) | 0.418 |
| Thalamus | 3 (6.25%) | 2 (15.38%) | 1 (2.86%) | 0.265 |
| Motor cortex | 1 (2.08%) | 1 (7.69%) | 0 | 0.271 |
| Large arterial encasement by the tumor | 1 (2.08 %) | 0 | 1 (2.86%) | 1 |
| Brainstem | 1 (2.08%) | 0 | 1 (2.86%) | 1 |
| Corpus callosum | 0 | 0 | 0 | NA |
| Median tumor volume | 27.35 | 24.35 | 34.25 | 0.1454 |
| MGMT status | ||||
| Methylated | 17 (36.17%) | 3 (6.38%) | 14 (29.79%) | 1* |
| Partially methylated | 6 (12.77%) | 3 (6.38%) | 3 (6.38%) | |
| Non-Methylated | 24 (51.06%) | 6 (12.77%) | 18 (36.30%) |
Bold values indicate statistical significance at the p < 0.05 level
*Methylated and partially methylated MGMT have been grouped together for the comparative analysis
DVT Deep venous thrombosis, PE Pulmonary embolus
Descriptive analysis of the surgical outcome and comparison between the ioUS and combined ioMRI + ioUS group
| Characteristics | Total | IoUS | ioUS+IoMRI | P value |
|---|---|---|---|---|
| Preoperative Karnofski performance scale (KPS) Score | ||||
| ≥70 | 26 (54.17 %) | 8 (61.54 %) | 18 (51.43 %) | 0.746 |
| <70 | 22 (45.83 %) | 5 (38.46 %) | 17 (48.57 %) | |
| Preoperative NANO scale (median) | 3 | 2.5 | 3 | 0.917 |
| Extent of resection | ||||
| Gross total resection (GTR) | 31 (64.58 %) | 7 (53.84 %) | 24 (68.58 %) | 0.498 |
| Near total resection (NTR) | 12 (25 %) | 3 (23.08 %) | 9 (25.71 %) | 1 |
| Subtotal resection (STR) | 5 (10.42 %) | 3 (23.08 %) | 2 (5.71 %) | 0.115 |
| Average length of surgery (minutes) | 169.7 ± 58.93 | 111.1 ± 51.32 | 189.7 ± 47.11 |
|
| Postoperative complications * | 8 (16.67 %) | 1 (7.69 %) | 7 (20 %) | 0.418 |
| Altered mental status | 4 (8.33 %) | 0 | 4 (11.43 %) | 0.563 |
| Urinary tract infection | 3 (6.25 %) | 0 | 3 (8.57 %) | 0.553 |
| Wound infection | 2 (4.17 %) | 0 | 2 (5.71 %) | 1 |
| Ileus | 2 (4.17 %) | 0 | 2 (5.71 %) | 1 |
| Postoperative hematoma (Managed without evacuation) | 1 (2.08 %) | 1 (7.69 %) | 0 | 0.271 |
| Pulmonary embolus | 1 (2.08 %) | 0 | 1 (2.86 %) | 1 |
| Perforator infarct | 1 (2.08 %) | 0 | 1 (2.86 %) | 1 |
| Atrial fibrillation | 1 (2.08 %) | 0 | 1 (2.86 %) | 1 |
| Average length of the hospital stay after the surgery (Days) | 4.583 ± 3.451 | 4.769 ± 2.891 | 4.514 ± 3.673 | 0.803 |
| Disposition | ||||
| Home | 23 (47.92 %) | 6 (46.15 %) | 17 (48.57 %) | 1 |
| Skilled nursing facilities (Short-term) | 16 (33.33 %) | 5 (38.46 %) | 11 (31.43 %) | 0.735 |
| Rehabilitation centers | 9 (18.75 %) | 2 (15.38 %) | 7 (20 %) | 1 |
| Functional outcome (Median) | ||||
| Postoperative KPS score (at discharge) |
| 70 | 70 | 0.964 |
| Postoperative follow-up KPS score (at 6 weeks follow-up) | 90 | 80 | 90 | 0.382 |
| Median Follow-up NANO scale | 1 | 1 | 1 | 0.722 |
| Changes in functional outcome | ||||
| Improvement | 28 (58.33 %) | 6 (46.15 %) | 22 (62.86 %) | 0.339 |
| Unchanged | 12 (25 %) | 5 (38.46 %) | 7 (20 %) | 0.263 |
| Worsening | 8 (16.67 %) | 2 (15.38 %) | 6 (17.14 %) | 1 |
| Chemoradiation protocols | ||||
| Stupp protocol | 24 (50 %) | 4 (30.77 %) | 20 (57.14 %) | 0.193 |
| Perry protocol | 5 (10.42 %) | 0 | 5 (14.29 %) | 0.304 |
| Hypofractionated radiation treatment alone | 8 (16.67 %) | 4 (30.77 %) | 4 (11.43 %) | 0.187 |
| No therapy | 11 (22.92 %) | 5 (38.46 %) | 6 (17.14 %) | 0.14 |
Bold values indicate statistical significance at the p < 0.05 level
*Some patients developed more than one complication
Logistic regression analysis of postoperative complications
| Characteristics | Odds Ratio (95% CI) | P value |
|---|---|---|
|
| ||
| Length of surgery | 1.023 (1.005–1.043) |
|
| Pre-operative KPS (KPS score ≥70 vs. KPS score <70) | 0.085 (0.010–0.767) |
|
| Length of hospital stay | 1.249 (1.025–1.522) |
|
| Tumor volume | 0.974 (0.934–1.016) | 0.226 |
| Pre-operative language deficit | 2.4 (0.471–12.22) | 0.292 |
| Gender | 0.36 (0.075–1.727) | 0.202 |
| Image guidance technique (ioUS vs. ioMRI + ioUS) | 0.333 (0.037–3.014) | 0.328 |
| Pre-operative motor deficit | 1.246 (0.258–6.031) | 0.784 |
| Age | 0.961 (0.810–1.139) | 0.644 |
| Pre-operative altered mental status | 0.556 (0.099–3.113) | 0.504 |
| Involvement of eloquent structures | 1.246 (0.257–6.031) | 0.784 |
|
| ||
| Length of surgery | 1.033 (1.006–1.06 ) |
|
| Length of hospital stay | 1.422 (1.046 –1.932) |
|
Bold values indicate statistical significance at the p < 0.05 level
KPS Karnofski Performance Scale; ioUS, intraoperative ultrasonography, ioMRI intraoperative magnetic resonance imaging. NANO, The Neurologic Assessment in Neuro-Oncology
Fig. 1Patients with pre-operative KPS score <70 demonstrated significant improvement 6-weeks after surgical
resection. Paired parallel axis dot plot showing significant functional improvement for patients
with pre-op KPS score <70 following the surgical resection (p<0.0001) (A) ,while no significant changes were observed in pre-op KPS score ≥ 70 group (B). Preoperative NANO scale improved significantly at postoperative follow-up assessment (P = 0.0036) from a preoperative median score of 3 to 1 at follow-up (C). Abbreviations: Pre-op, preoperative; post-op, postoperative; KPS, Karnofski Performance Scale; NANO, The Neurologic Assessment in Neuro-Oncology
Univariate and Multivariate Analysis of overall survival with Cox proportional hazards model
| Characteristics | Hazard ratio (95% CI) | P value |
|---|---|---|
|
| ||
| Adjuvant treatment | 0.075 (0.028–0.204) |
|
| Post-operative complications | 4.119 (1.753–9.679) |
|
| Pre-operative KPS (KPS score ≥70 vs. KPS score <70) | 0.559 (0.301–1.040) | 0.066 |
| EOR (GTR+NTR vs. STR) | 0.540 (0.209–1.400) | 0.205 |
| MGMT * (methylated and partially methylated vs. unmethylated) | 0.694 (0.366–1.317) | 0.264 |
| Gender | 1.431 (0.762–2.690) | 0.265 |
| Image guidance technique (ioUS vs. ioMRI + ioUS) | 1.450 (0.712–2.954) | 0.306 |
| Pre-operative altered mental status | 1.290 (0.677–2.460) | 0.439 |
| Involvement of eloquent structures | 1.192 (0.621–2.289) | 0.598 |
| Pre-operative motor deficit | 1.175 (0.606–2.281) | 0.633 |
| Tumor volume | 0.998 (0.990–1.008) | 0.802 |
| Follow-Up KPS (KPS score ≥70 vs. KPS score <70) | 1.044 (0.495–2.203) | 0.910 |
|
| ||
| EOR (GTR+NTR vs. STR) | 0.329 (0.121–0.896) |
|
| Post-operative complications | 3.620 (1.433–9.144) |
|
| Adjuvant treatment | 0.144 (0.057–0.362) |
|
Bold values indicate statistical significance at the p < 0.05 level
*An independent univariate analysis was further performed to assess the impact of MGMT status on overall survival in patients who had MGMT status determined as “methylated” or “unmethylated” and received temozolomide treatment (n = 29), (P = 0.172, HR:0.550, 95% CI 0.233 – 1.30)
Abbreviations: KPS, Karnofski Performance Scale; ioUS, intraoperative ultrasonography; ioMRI, intraoperative magnetic resonance imaging; EOR, Extent of resection; GTR, gross total resection; NTR, near total resection; STR, subtotal resection